Evidence map›Paper›PMID 39516345›Full record

ReviewBJC reports2024

Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management.

Aziz A A Alnakli, Abidali Mohamedali, Benjamin Heng, Charles Chan, Joo-Shik Shin, Michael Solomon, Pierre Chapuis, Gilles J Guillemin, Mark S Baker, Seong Beom Ahn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aziz A A AlnakliMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW, Australia.
Abidali MohamedaliMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW, Australia.
Benjamin HengMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW, Australia.
Charles ChanDepartment of Anatomical Pathology, NSW Health Pathology, Concord Hospital, Sydney, NSW, Australia.
Joo-Shik ShinDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia.
Michael SolomonDepartment of Colorectal Surgery RPAH & Institute of Academic Surgery at Sydney Medical School, University of Sydney, Sydney, Australia.
Pierre ChapuisConcord Institute of Academic Surgery, Concord Clinical School, Faculty of Medicine and Health, Concord Hospital, University of Sydney, Sydney, NSW, Australia.
Gilles J GuilleminInstitut Pertanian Bogor University, Bogor, Indonesia.
Mark S BakerMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW, Australia.
Seong Beom AhnMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW, Australia. charlie.ahn@mq.edu.au.ORCID http://orcid.org/0000-0001-5907-3544

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) poses a significant threat to many human lives worldwide and survival following resection is predominantly stage dependent. For early-stage cancer, patients are not routinely advised to undergo additional post-operative adjuvant chemotherapy. Acceptable clinical management guidelines are well established for patients in pTNM stages I, III and IV. However, recommendations for managing CRC stage II patients remain controversial and many studies have been conducted to segregate stage II patients into low- and high-risk of recurrence using genomic, transcriptomic and proteomic molecular markers. As proteins provide valuable insights into cellular functions and disease state and have a relatively easy translation to the clinic, this review aims to discuss potential prognostic protein biomarkers proposed for predicting tumour relapse in early-stage II CRC. It is suggested that a panel of markers may be more effective than a single marker and further evaluation is required to translate these into clinical practice.

Identifiers

PMID39516345
PMCPMC11523985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.